Evaluation and treatment of asthma: An overview

American Journal of Managed Care

Volumn 11, Issue SUPPL. 14, 2005, Pages

  Corren, Jonathan ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Allergy Research Foundation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; CICLESONIDE; CORTICOSTEROID; FLUNISOLIDE; FLUORINATED HYDROCARBON; FLUTICASONE; FLUTICASONE PROPIONATE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MOMETASONE FUROATE; MONTELUKAST; OMALIZUMAB; PLACEBO; TRIAMCINOLONE ACETONIDE; ZAFIRLUKAST; ZILEUTON;

ASTHMA; BODY PLETHYSMOGRAPHY; CONFERENCE PAPER; DISEASE SEVERITY; EVALUATION; EXPIRATORY FLOW; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; METERED DOSE INHALER; OUTCOMES RESEARCH; PATIENT CARE; PATIENT MONITORING; PATIENT REFERRAL; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT PLANNING;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; DRUG MONITORING; DRUG THERAPY, COMBINATION; HUMANS; LEUKOTRIENE ANTAGONISTS; PHYSICAL EXAMINATION; PRACTICE GUIDELINES; RESPIRATORY FUNCTION TESTS;

EID: 28344433102     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (26)

1. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033-1039.
2. Busse WW, Lemanske RF Jr. Asthma. N Engl J Med. 2001;344:350-362.
3. Robinson DS, Hamid Q, Ying S, et al. Prominent TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;326:298-304.
4. Platts-Mills TA. The role of immunoglobulin E in allergy and asthma. Am J Respir Crit Care Med. 2001;164:S1-S5.
5. van Weel C. Underdiagnosis of asthma and COPD: is the general practitioner to blame? Monaldi Arch Chest Dis. 2002;57:65-68.
6. Greisner WA 3rd, Settipane RJ, Settipane GA. Natural history of hay fever: a 23-year follow-up of college students. Allergy Asthma Proc. 1998;19:271-275.
7. Wright AL. The epidemiology of the atopic child: who is at risk for what? J Allergy Clin Immunol. 2004;113(suppl 1):S2-S7.
8. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program (NAEPP) Expert Panel Report: Guidelines for the Diagnosis and Management of Asthma-Update on Selected Topics 2002. National Institutes of Health Publication 02-5074. Bethesda, Md: US Department of Health and Human Services; 2003.
9. Smith AD, Cowan JO, Brassett KP, Herbison GP, Taylor DR. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med. 2005;352:2163-2173.
10. Global Strategy for Asthma Management and Prevention. NIH Publication 02-3659. Issued January 1995 (updated 2002).
11. National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program (NAEPP), Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma-Clinical Practice Guidelines. National Institutes of Health Publication 97-4051. Bethesda, Md: US Department of Health and Human Services; 1997.
12. Sin DD, Man J, Sharpe H, Gan WQ, Man SF. Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA. 2004;292:367-376.
13. Donahue JG, Weiss ST, Livingston JM, Goetsch MA, Greineder DK, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA. 1997;277:887-891.
14. Chrousos GP, Ghaly L, Shedden A, Iezzoni DG, Harris AG. Effects of mometasone furoate dry powder inhaler and beclomethasone dipropionate hydrofluoroalkane and chlorofluorocarbon on the hypothalamic-pituitary-adrenal axis in asthmatic subjects. Chest. 2005;128:70-77.
15. Reynolds NA, Scott LJ. Ciclesonide. Drugs. 2004; 64:511-519.
16. Shafazand S, Colice G. Flunisolide HFA for the treatment of asthma: an old friend reformulated. Expert Opin Pharmacother. 2004;5:1163-1173.
17. Allen DB. Inhaled steroids for children: effects on growth, bone, and adrenal function. Endocrinol Metab Clin North Am. 2005;34:555-564.
18. Agertoft L, Pedersen S. Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. N Engl J Med. 2000;343:1064-1069.
19. Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch Intern Med. 1999;159:941-955.
20. Kemp JP. Recent advances in the management of asthma using leukotriene modifiers. Am J Respir Med. 2003;2:139-156.
21. Chervinsky P, Philip G, Malice MP, et al. Montelukast for treating fall allergic rhinitis: effect of pollen exposure in 3 studies. Ann Allergy Asthma Immunol. 2004;92:367-373.
22. Phipatanakul W, Greene C, Downes SJ, et al. Montelukast improves asthma control in asthmatic children maintained on inhaled corticosteroids. Ann Allergy Asthma Immunol. 2003;91:49-54.
23. Ram FS, Cates CJ, Ducharme FM. Long-acting beta 2-agonists versus anti-leukotrienes as add-on therapy to inhaled corticosteroids for chronic asthma. Cochrane Database Syst Rev. 2005;CD003137.
24. Corren J, Casale T, Deniz Y, et al. Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma. J Allergy Clin Immunol. 2003;111:87-90.
25. Vollmer WM, Markson LE, O'Connor E, et al. Association of asthma control with health care utilization and quality of life. Am J Respir Crit Care Med. 1999;160:1647-1652.
26. Schatz M, Cook EF, Nakahiro R, Petitti D. Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma. J Allergy Clin Immunol. 2003;111:503-508.